Novo Nordisk sells $13 billion worth of semaglutide in H1 2024

On August 7, 2024, Novo Nordisk announced its 2024H1 performance, with a total revenue of 133.409 billion Danish kroner (approximately 19.366 billion US dollars, calculated at this year's average exchange rate: 1 Danish kroner=0.14516 US dollars, the same below), a year-on-year increase of 25% (the full increase is calculated at a fixed exchange rate CER)

In the first half of the year, the revenue of diabetes and obesity care business was DKK 125.049 billion (USD 18.152 billion), up 27% year on year. Among them, the sales of GLP-1 diabetes drugs increased by 32% year-on-year to DKK 72.017 billion (US $10.454 billion), and Novo Nordisk accounted for 56.0% of the global GLP-1 diabetes drug market; The sales of obesity drugs increased by 37% year-on-year to 24.939 billion Danish kroner (3.62 billion US dollars), and Novo Nordisk holds a 91% market share in the global obesity drug market

Ozempic injection of semaglutide has maintained a high growth rate of 36% for many years, with a half year revenue of 56.685 billion Danish kroner (8.228 billion US dollars); The revenue of Rybelsus oral semaglutide tablets was 10.931 billion Danish kroner (1.587 billion US dollars), a year-on-year increase of 32%; Wegovy generated 21.036 billion Danish kroner (3.054 billion US dollars) in revenue from the injection of semaglutide for weight loss, a year-on-year increase of 74%. The three products totaled 88.652 billion Danish kroner in the first half of the year, or 12.869 billion US dollars, and are expected to easily surpass 25 billion US dollars for the whole year.

In terms of other business areas, revenue from insulin products has resumed growth (26.977 billion Danish kroner,+10%); The revenue of rare disease business remained basically the same as the same period last year, with a revenue of 8.36 billion Danish kroner (-3%). Novo Nordisk's performance in China reached 9.469 billion Danish kroner (1.341 billion US dollars,+10%) in H1 2024, with GLP-1 business contributing 3.684 billion Danish kroner (535 million US dollars,+23%). At present, Novo Nordisk is the main leader of the GLP-1 diabetes drug market in China, accounting for about 79.0% of the market share.In terms of other business areas, revenue from insulin products has resumed growth (26.977 billion Danish kroner,+10%); The revenue of rare disease business remained basically the same as the same period last year, with a revenue of 8.36 billion Danish kroner (-3%). Novo Nordisk's performance in China reached 9.469 billion Danish kroner (1.341 billion US dollars,+10%) in H1 2024, with GLP-1 business contributing 3.684 billion Danish kroner (535 million US dollars,+23%). At present, Novo Nordisk is the main leader of the GLP-1 diabetes drug market in China, accounting for about 79.0% of the market share.

In China, the sales of Ozempic (semaglutide injection, hypoglycemic) have reached 2.935 billion Danish kroner ($426 million,+38%). In January of this year, Simeglutide tablets Rybelsus were also approved for marketing in China, making it the first oral GLP-1 receptor agonist approved for marketing in the country. In less than half a year, Rybelsus sold 108 million Danish kroner ($16 million,+67%) in China.

 Semeglutide is a GLP-1 receptor agonist that can stimulate insulin production and inhibit glucagon secretion, reducing appetite and food intake. Smeaglutide was initially approved for marketing as a therapeutic drug for type 2 diabetes (trade name: Ozempic). In view of its remarkable effect in weight loss, FDA approved it for the treatment of ordinary obese patients (trade name: Wegovy) in June 2021. It is the first new drug approved by the US FDA to control ordinary obesity or overweight since 2014. The drug was later approved by the European Union for the treatment of obesity in the same year. About Novo Nordisk

Novo Nordisk was founded in 1923 and is a globally leading biopharmaceutical company headquartered in Copenhagen, the capital of Denmark. Our goal is to promote change to combat diabetes, obesity, rare blood diseases, endocrine disorders and other serious chronic diseases. To achieve this goal, we lead scientific breakthroughs, expand the accessibility of our company's drugs, and are committed to preventing and ultimately curing diseases. Novo Nordisk has approximately 47000 employees in 80 countries and regions worldwide, providing products and services to over 168 countries and regions worldwide.